{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:01:32Z","timestamp":1787806892368,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.05.038","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T21:45:59Z","timestamp":1591393559000},"page":"640-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Tamrintamab pamozirine (SC-003) in patients with platinum-resistant\/refractory ovarian cancer: Findings of a phase 1 study"],"prefix":"10.1016","volume":"158","author":[{"given":"Erika","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2018","key":"10.1016\/j.ygyno.2020.05.038_bb0005","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.05.038_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40661-017-0050-0","article-title":"Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?","volume":"4","author":"Herzog","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0020","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0030","doi-asserted-by":"crossref","unstructured":"W. R. Wiedemeyer, S. Bheddah, C. Saechao, et al., SC-003, an antibody-drug conjugate targeting dipeptidase 3, exhibits potent anti-tumor activity in patient-derived xenograft models of high grade serous ovarian cancer, Presented at the 12th Biennial Ovarian Cancer Research Symposium, September 13\u201315, 2018, Seattle, WA, Poster NT-113.","DOI":"10.1158\/1557-3265.OVCASYMP18-NT-113"},{"key":"10.1016\/j.ygyno.2020.05.038_bb0035","series-title":"Targeting signalling pathways and the immune microenvironment of cancer cells \u2013 a clinical update","author":"Clara","year":"2019"},{"key":"10.1016\/j.ygyno.2020.05.038_bb0040","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/labinvest.2013.92","article-title":"Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathology in the 21st century","volume":"93","author":"Williams","year":"2013","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0045","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0050","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy279.425","article-title":"Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: preliminary phase 1 results from study M15-891","volume":"29","author":"Powderly","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0060","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-09-1961","article-title":"Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee","volume":"16","author":"Ivy","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0065","unstructured":"National Institutes of Health. U.S. National Library of Medicine, ClinicalTrials.gov. http:\/\/www.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02539719, 2019 (27 February 2020)."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jri.2011.04.010","article-title":"Molecular characterization and expression of dipeptidase 3, a testis-specific membrane-bound dipeptidase: complex formation with TEX101, a germ-cell-specific antigen in the mouse testis","volume":"90","author":"Yoshitake","year":"2011","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0075","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1074\/mcp.RA118.000749","article-title":"Discovery of a human testis-specific protein complex TEX101-DPEP3 and selection of its disrupting antibodies","volume":"17","author":"Schiza","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ygyno.2020.05.038_bb0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2020.05.038_bb0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0090","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2020.05.038_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820311239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820311239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:46Z","timestamp":1758772366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820311239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820311239"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.038","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tamrintamab pamozirine (SC-003) in patients with platinum-resistant\/refractory ovarian cancer: Findings of a phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}